+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Ursodeoxycholic acid and tauroursodeoxycholic acid suppress choroidal neovascularization in a laser-treated rat model

Ursodeoxycholic acid and tauroursodeoxycholic acid suppress choroidal neovascularization in a laser-treated rat model

Journal of Ocular Pharmacology and Therapeutics 26(3): 223-229

The aim of this study was to investigate the suppressing effects of systemically administered ursodeoxycholic acid (UDCA) and tauroursodeoxycholic acid (TUDCA) on choroidal neovascularization (CNV) in a laser-treated rat model. CNV was induced by argon laser photocoagulation in the right eye of each animal. UDCA 500 mg/kg, TUDCA 100 mg/kg, or vehicle was intraperitoneally injected at 24 h before and daily after laser treatment. Fourteen days after laser treatment, fluorescein angiography was performed to evaluate leakage from CNV and eyes were enucleated for histologic evaluation. Vascular endothelial growth factor (VEGF) levels in the retina were measured using enzyme-linked immunosorbent assay at 3 days after laser treatment and were compared between the UDCA, TUDCA, and control groups. The proportion of CNV lesions showing clinically significant fluorescein leakage was lower in the UDCA and TUDCA groups (42%, P = 0.0124; and 46%, P = 0.0292) than in the control group (67%). CNV lesion dimensions including CNV area and CNV/choroid thickness ratio were also significantly reduced in the UDCA and TUDCA groups (7,664 +/- 630 microm(2), P < 0.001 and 8,558 +/- 570 microm(2), P < 0.001; 2.35 +/- 0.16, P = 0.026 and 2.27 +/- 0.15, P = 0.003) compared with the control group (12,147 +/- 661 microm(2) and 3.10 +/- 0.27). The VEGF level in the retina after laser treatment was lower in the TUDCA group than that in the control group (9.0 +/- 2.7 pg/mg vs. 29.4 +/- 8.2 pg/mg, P = 0.032), whereas the UDCA group showed no difference. The systemic administration of UDCA and TUDCA suppressed laser-induced CNV formation in rats, which might be associated with anti-inflammatory action. The result indicates that UDCA and TUDCA are potential candidate drugs for the treatment of many CNV-related retinal diseases, including age-related macular degeneration.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 056788958

Download citation: RISBibTeXText

PMID: 20565307

DOI: 10.1089/jop.2010.0012

Related references

Hepatoprotection in ethinylestradiol-treated rats is provided by tauroursodeoxycholic acid, but not by ursodeoxycholic acid. Journal Of Gastroenterology & Hepatology. 10(3): 261-269, 1995

Hepatoprotection in ethynylestradiol-treated rats in provided by tauroursodeoxycholic acid, but not by ursodeoxycholic acid. Hepatology 18(4 PART 2): 311A, 1993

Toxicity of ethanol and acetaldehyde in hepatocytes treated with ursodeoxycholic or tauroursodeoxycholic acid. Biochimica et Biophysica Acta 1644(1): 37-45, 2004

Predictors of Choroidal Neovascularization in Eyes Treated With Subthreshold Diode Grid Laser Therapy to Prevent Choroidal Neovascularization; Results From the Unilateral Arm of the PTAMD Study. ARVO Annual Meeting Abstract Search & Program Planner : Abstract No 1211, 2002

Annexin A2 promotes choroidal neovascularization by increasing vascular endothelial growth factor expression in a rat model of argon laser coagulation-induced choroidal neovascularization. Chinese Medical Journal 123(6): 713-721, 2010

Tauroursodeoxycholic acid, ursodeoxycholic acid and gallbladder motility in gallstone patients and healthy subjects. Italian Journal of Gastroenterology 28(2): 111-113, 1996

Ursodeoxycholic acid versus tauroursodeoxycholic acid Crossover study of their absorption and biliary enrichment in man. Hepatology 24(4 PART 2): 372A, 1996

Ursodeoxycholic acid but not tauroursodeoxycholic acid inhibits proliferation and differentiation of human subcutaneous adipocytes. Plos One 8(12): E82086, 2014

Neither ursodeoxycholic acid nor tauroursodeoxycholic acid protects rabbit hepatocytes from toxic bile acids. Gastroenterology 98(5 PART 2): A600, 1990

Ursodeoxycholic acid and not tauroursodeoxycholic acid prevents the ethynylestradiol induced intrahepatic cholestasis in rats. Gastroenterology 98(5 PART 2): A651, 1990

Ca2+-dependent cytoprotective effects of ursodeoxycholic and tauroursodeoxycholic acid on the biliary epithelium in a rat model of cholestasis and loss of bile ducts. American Journal of Pathology 168(2): 398-409, 2006

Chronic administration of ursodeoxycholic and tauroursodeoxycholic acid changes microsomal membrane lipid content and fatty acid composition in rats. Biochemical & Biophysical Research Communications. 220(3): 479-483, 1996

Pentoxifylline, but not ursodeoxycholic acid or tauroursodeoxycholic acid inhibits the proliferative effect of sera samples from primary biliary cirrhosis patients. Hepatology Research 7(2): 94-104, 1997

Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Archives of Ophthalmology 119(3): 399-404, 2001

Effect of brimonidine on retinal and choroidal neovascularization in a mouse model of retinopathy of prematurity and laser-treated rats. Investigative Ophthalmology and Visual Science 52(8): 5424-5431, 2011